DexCom price target raised to $130 from $120 at Stifel

Stifel analyst Mathew Blackman raised the firm’s price target on DexCom to $130 from $120 and keeps a Buy rating on the shares. He believes the company is set up for outsized growth in 2023 and beyond and in the shortest-term, even in a scenario where 2023 initial guidance is "conservative," he suspects "any share dislocation will be transient," Blackman tells investors.